Home > Publications database > Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. > print

001     177206
005     20240229133733.0
024 7 _ |a 10.1016/j.ccell.2021.09.012
|2 doi
024 7 _ |a pmid:34678152
|2 pmid
024 7 _ |a 1535-6108
|2 ISSN
024 7 _ |a 1878-3686
|2 ISSN
024 7 _ |a altmetric:115566339
|2 altmetric
037 _ _ |a DKFZ-2021-02340
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Liu, Anthony P Y
|b 0
245 _ _ |a Serial assessment of measurable residual disease in medulloblastoma liquid biopsies.
260 _ _ |a New York, NY
|c 2021
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1642495051_12953
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2021 Nov 8;39(11):1519-1530.e4
520 _ _ |a Nearly one-third of children with medulloblastoma, a malignant embryonal tumor of the cerebellum, succumb to their disease. Conventional response monitoring by imaging and cerebrospinal fluid (CSF) cytology remains challenging, and a marker for measurable residual disease (MRD) is lacking. Here, we show the clinical utility of CSF-derived cell-free DNA (cfDNA) as a biomarker of MRD in serial samples collected from children with medulloblastoma (123 patients, 476 samples) enrolled on a prospective trial. Using low-coverage whole-genome sequencing, tumor-associated copy-number variations in CSF-derived cfDNA are investigated as an MRD surrogate. MRD is detected at baseline in 85% and 54% of patients with metastatic and localized disease, respectively. The number of MRD-positive patients declines with therapy, yet those with persistent MRD have significantly higher risk of progression. Importantly, MRD detection precedes radiographic progression in half who relapse. Our findings advocate for the prospective assessment of CSF-derived liquid biopsies in future trials for medulloblastoma.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a biomarkers
|2 Other
650 _ 7 |a cell-free DNA
|2 Other
650 _ 7 |a cerebrospinal fluid
|2 Other
650 _ 7 |a childhood cancer
|2 Other
650 _ 7 |a liquid biopsy
|2 Other
650 _ 7 |a measurable residual disease
|2 Other
650 _ 7 |a medulloblastoma
|2 Other
650 _ 7 |a microscopic residual disease
|2 Other
650 _ 7 |a minimal residual disease
|2 Other
650 _ 7 |a relapse disease
|2 Other
700 1 _ |a Smith, Kyle S
|b 1
700 1 _ |a Kumar, Rahul
|b 2
700 1 _ |a Paul, Leena
|b 3
700 1 _ |a Bihannic, Laure
|b 4
700 1 _ |a Lin, Tong
|b 5
700 1 _ |a Maass, Kendra K
|0 P:(DE-He78)5100059e746b377e2e0a37c0e24f6bf7
|b 6
|u dkfz
700 1 _ |a Pajtler, Kristian W
|0 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d
|b 7
|u dkfz
700 1 _ |a Chintagumpala, Murali
|b 8
700 1 _ |a Su, Jack M
|b 9
700 1 _ |a Bouffet, Eric
|b 10
700 1 _ |a Fisher, Michael J
|b 11
700 1 _ |a Gururangan, Sridharan
|b 12
700 1 _ |a Cohn, Richard
|b 13
700 1 _ |a Hassall, Tim
|b 14
700 1 _ |a Hansford, Jordan R
|b 15
700 1 _ |a Klimo, Paul
|b 16
700 1 _ |a Boop, Frederick A
|b 17
700 1 _ |a Stewart, Clinton F
|b 18
700 1 _ |a Harreld, Julie H
|b 19
700 1 _ |a Merchant, Thomas E
|b 20
700 1 _ |a Tatevossian, Ruth G
|b 21
700 1 _ |a Neale, Geoffrey
|b 22
700 1 _ |a Lear, Matthew
|b 23
700 1 _ |a Klco, Jeffery M
|b 24
700 1 _ |a Orr, Brent A
|b 25
700 1 _ |a Ellison, David W
|b 26
700 1 _ |a Gilbertson, Richard J
|b 27
700 1 _ |a Onar-Thomas, Arzu
|b 28
700 1 _ |a Gajjar, Amar
|b 29
700 1 _ |a Robinson, Giles W
|b 30
700 1 _ |a Northcott, Paul A
|b 31
773 _ _ |a 10.1016/j.ccell.2021.09.012
|g p. S1535610821005018
|0 PERI:(DE-600)2074034-7
|n 11
|p 1519-1530.e4
|t Cancer cell
|v 39
|y 2021
|x 1535-6108
909 C O |p VDB
|o oai:inrepo02.dkfz.de:177206
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)5100059e746b377e2e0a37c0e24f6bf7
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2021
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER CELL : 2019
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2021-01-26
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-26
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-01-26
915 _ _ |a IF >= 25
|0 StatID:(DE-HGF)9925
|2 StatID
|b CANCER CELL : 2019
|d 2021-01-26
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21